Showing 1 - 6 results of 6 for search 'Hiva Azizi', query time: 0.03s Refine Results
  1. 1
    RNA secondary structure and nucleotide composition of the conserved hallmark sequence of Leishmania SIDER2 retroposons are essential for endonucleolytic cleavage and mRNA degradation.

    RNA secondary structure and nucleotide composition of the conserved hallmark sequence of Leishmania SIDER2 retroposons are essential for endonucleolytic cleavage and mRNA degradati... by Hiva Azizi, Tatiany P Romão, Karen Santos Charret, Prasad K Padmanabhan, Osvaldo P de Melo Neto, Michaela Müller-McNicoll, Barbara Papadopoulou

    Published 2017-01-01
    Get full text
    Article
  2. 2
    Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis.

    Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis. by Noushin Saljoughian, Tahereh Taheri, Farnaz Zahedifard, Yasaman Taslimi, Fatemeh Doustdari, Azam Bolhassani, Delaram Doroud, Hiva Azizi, Kazem Heidari, Mohammad Vasei, Nabiollah Namvar Asl, Barbara Papadopoulou, Sima Rafati

    Published 2013-01-01
    Get full text
    Article
  3. 3
    Development and characterization of influenza M2 ectodomain and/or hemagglutinin stalk-based dendritic cell-targeting vaccines

    Development and characterization of influenza M2 ectodomain and/or hemagglutinin stalk-based dendritic cell-targeting vaccines by Titus Abiola Olukitibi, Titus Abiola Olukitibi, Zhujun Ao, Zhujun Ao, Hiva Azizi, Mona Mahmoudi, Mona Mahmoudi, Kevin Coombs, Darwyn Kobasa, Darwyn Kobasa, Gary Kobinger, Gary Kobinger, Xiaojian Yao, Xiaojian Yao

    Published 2022-08-01
    Get full text
    Article
  4. 4
    A novel intradermal tattoo-based injection device enhances the immunogenicity of plasmid DNA vaccines

    A novel intradermal tattoo-based injection device enhances the immunogenicity of plasmid DNA vaccines by Alejandro M. Gomez, George (Giorgi) Babuadze, Marc-André Plourde-Campagna, Hiva Azizi, Alice Berger, Robert Kozak, Marc-Antoine de La Vega, Ara XIII, Maedeh Naghibosadat, Marie-Edith Nepveu-Traversy, Jean Ruel, Gary P. Kobinger

    Published 2022-12-01
    Get full text
    Article
  5. 5
    Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV

    Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV by Hiva Azizi, Jason P. Knapp, Yue Li, Alice Berger, Marc-Alexandre Lafrance, Jannie Pedersen, Marc-Antoine de la Vega, Trina Racine, Chil-Yong Kang, Jamie F. S. Mann, Jimmy D. Dikeakos, Gary Kobinger, Eric J. Arts

    Published 2023-05-01
    Get full text
    Article
  6. 6
    Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen

    Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen by Joseph Jelinski, Monika M. Kowatsch, Marc-Alexandre Lafrance, Alice Berger, Jannie Pedersen, Hiva Azizi, Yue Li, Florine Scholte, Alejandro Gomez, Natasha Hollett, Toby Le, Matthew Wade, Hugues Fausther-Bovendo, Marc-Antoine de La Vega, George Babuadze, Ara, Claude Lamarre, Trina Racine, Chil-Yong Kang, Xiao-Jian Yao, Galit Alter, Eric Arts, Keith R. Fowke, Gary P. Kobinger

    Published 2023-12-01
    Get full text
    Article

Search Tools: